Medical Marijuana Inc., First Company to Provide Mexican Citizens Access to Medical Marijuana, Congratulates Cannabis Advocates in Mexico on Medical Cannabis Legalization
SAN DIEGO, June 22, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that it applauds Mexico President Pena Nieto for signing a bill into law June 19 that officially legalized the cultivation, production, and use of cannabis products with less than 1% THC for medical use in Mexico.
The new law, which was approved by Mexico lawmakers earlier this year by an overwhelming majority, will direct Mexico’s ministry of Health to draft and implement policies to regulate the use, importation, and production of pharmaceutical products derived from cannabidiol (CBD)-dominant/low-THC cannabis.
“This historic change in policy for this critical Latin America nation is a momentous achievement for the over 120 million Mexican citizens who can now benefit from the therapeutic benefits of medical cannabis, plus for the medical cannabis advocates who have worked diligently for many years to make the therapeutic use of cannabinoids legal in the Country,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We are extremely proud to have been the first company to provide Mexico citizens with access to a medical product based on cannabis (hemp CBD) and applaud President Nieto and Mexico lawmakers for their commitment to cannabis reform. We look forward to continuing our support of Mexico as it moves forward with this new era of medical cannabis for those in need.
“With medical cannabis fully legal in Canada and now in Mexico, we wonder how long it will be before the United States joins the rest of North America in reforming laws at the national/federal level. With 30 U.S. States approving medical cannabis and 17 others with CBD-only laws, we feel the real crime in this matter is the lack of progressive leadership shown by our own federal government. The science 100% supports this, the people fully support this, and the opioid crisis is totally out of control. We, the people, demand answers from our leaders.”
Medical Marijuana, Inc., started exporting to Mexico to help families gain access to CBD hemp oil RSHO-X™ after the Health Department of Mexico, COFEPRIS, issued the country’s first-ever government permits on February 2, 2016, to two families, including the Maldonado family whose daughter suffered from a severe form of epilepsy.
Medical Marijuana, Inc.’s HempMeds® Mexico furthered its efforts to encourage cannabis reform through its close ties with its nonprofit partner in Mexico, the Por Grace Foundation. Following a 2015 court ruling, eight-year-old Grace Elizalde became the first patient in Mexico to legally access and use CBD. Grace’s father, Raul Elizalde, started the Por Grace Foundation to further access to CBD by advocating for patients, hosting public forums, and meeting with government officials. Raul joined President Peña Nieto on stage last April as the leader announced the country would pursue medical cannabis reform.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC PINK: MJNA) and the Company’s exclusive master distributor and contracted marketing company, handling sales and distribution.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.